long intergenic non-protein coding RNA 2171Genealiases: []
Q-omics provides the consensus-scored LINC02171 profile across patient tissues and cancer cell-line models. LINC02171 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02171 is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, LINC02171 RNA expression shows 6,263 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, KIRC, and STAD as cancer lineages where LINC02171 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02171 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02171 survival associations across molecular data types. LINC02171 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02171 RNA expression–survival associations across cancer types. High LINC02171 expression shows unfavorable associations in BRCA, HNSC, CESC, STAD and THYM, but favorable associations in KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02171 RNA expression.
This table summarizes LINC02171 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02171. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02171 shows lower tumor expression in KIRC, KIRP and KICH. The KIRC box plot shows higher LINC02171 RNA expression in normal versus tumor tissue (log2 FC = −0.017, t-test p < 0.001).
This table shows molecular features associated with LINC02171 in patient tissues and cancer cell lines. In patient samples, LINC02171 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
